Gastroenterology Research and Practice / 2016 / Article / Tab 3

Research Article

Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience

Table 3

Comparison of demographic characteristics, tumor factors, and treatment modalities between male and female patients.

Female (%)
mean ± SD
Male (%)
mean ± SD
value

Hypertension4161.20%8248.80%0.086
Diabetes4262.70%9456.00%0.345
Underlying cause of liver disease
 Viral hepatitis5683.60%12272.60%0.077
 Nonviral hepatitis1116.40%4627.40%
Symptoms at presentation3653.70%8751.80%0.787
Noncirrhotic liver710.40%3722.00%0.049
Number of tumors
 Single3349.30%8450.00%0.019
 Two lesions1522.40%1810.70%
 Multiple (≥3)1928.40%6639.30%
Metastasis57.50%2615.50%0.101
Vascular invasion710.40%2112.50%0.661
Child-Turcotte-Pugh score
 A3146.30%10461.90%0.08
 B2638.80%4929.20%
 C1014.90%158.90%
BCLC stages
 Stage 023.00%63.60%0.011
 Stage A3247.80%4728.00%
 Stage B1522.40%6639.30%
 Stage C811.90%3420.20%
 Stage D1014.90%158.90%
Portal vein thrombosis57.50%3118.50%0.035
 Initial intervention
  Best supportive care2334.30%6438.10%0.013
  Chemoembolization1319.40%3923.20%
  Ablation therapy2740.30%3722.00%
  Sorafenib00.00%2011.90%
  Surgical resection34.50%63.60%
  Transplant11.50%21.20%
AGE63 ± 1066 ± 110.028
BMI29.75 ± 6.5126.75 ± 5.380.001
Tumor size (cm)3.69 ± 2.676.53 ± 5.630.000
Bilirubin, μmol/L31.1 ± 29.845.7 ± 132.50.181
Albumin, g/L31 ± 734 ± 70.002
AST, U/L92 ± 7797 ± 1120.723
ALT, U/L58 ± 4267 ± 650.204
INR1.4 ± 0.71.2 ± 0.20.018
Creatinine90 ± 91.790 ± 49.30.997
AFP13128.1 ± 7510059.3 ± 310.752
Platelets, ×109/L174 ± 113212 ± 1420.035
MELD11.9 ± 5.911.1 ± 4.70.312

SD: standard deviation; BMI: body mass index; MELD: model for end-stage liver disease; AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; INR: international normalized ratio; BCLC: Barcelona Clinic Liver Cancer.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.